Sen. Gerald Hocker

This Act replaces the stillbirth certificate with a certificate of birth resulting in stillbirth, clarifies what documentation is required upon the occurrence of a stillbirth, and makes technical corrections to the Vital Statistics laws to accurately reflect current practices. This Act does not change the current reporting requirements regarding births or deaths. This Act shall be known as "Lorenzo's Law" in memory of Lorenzo Joseph DiSalvo who was born on July 3, 2016. Lorenzo is the son of Kimberly Ann DiSalvo and Chad William DiSalvo. His maternal grandparents are Thomas and Cheryl Favoroso and paternal grandparents are Joseph (deceased) and Marla DiSalvo.

This legislation adopts the NAIC’s Corporate Governance Annual Disclosure Model Act, and requires Delaware-domiciled insurers to provide to the Commissioner on an annual basis a summary of the insurer’s or insurance group’s corporate governance structures, policies and practices to permit the Commissioner to gain and maintain an understanding of the insurer’s corporate governance framework.

This Act updates Delaware's human trafficking crime to prohibit the same acts that are included in the federal Justice for Victims of Trafficking Act of 2015.

This legislation authorizes the Department to operate its principal office in the Dover area and an additional branch office in Sussex County.

This Bill clarifies that every prescriber holding a controlled substance registration must be registered with the Prescription Monitoring Program. Further, prescribers who receive a CSR (controlled substances registration) for the first time must register with the Prescription Monitoring Program within 90 days.

This bill removes the requirement that the Governor must declare a State of Emergency before issuing a Level 1 Driving Warning.

This Act provides greater clarity of language, condenses duplicative statutes and deletes statues that are irrelevant to daily operations of the Professional Licensing Section’s regulation of private security, private investigative and armored car agencies.

This Act provides clearer language concerning license requirements, gives licensees a much clearer understanding of prohibited acts, discipline and penalties; and grants the ability of the Professional Licensing Section to promulgate regulations, and additional powers needed to oversee this chapter.

Under this Act, a pharmacist who dispenses narloxone under an established set of circumstances is not subject to disciplinary or other adverse action under any professional licensing statute or criminal liability, or liable for damages related to injuries or death sustained in connection with administering the drug, unless it is established that the pharmacist caused the injuries or death wilfully, wantonly, or by gross negligence.

This Bill adds 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) to Schedule I of the Uniform Controlled Substances Act. U-47700, also known as “Pink,” is a synthetic opioid recently encountered by law enforcement and public health officials and is being abused for its opioid properties. It is available over the Internet and is marketed as a “research chemical.” The safety risks to users are significant and the public health risks include large numbers of drug treatment admissions, emergency room visits and fatal overdoses. On November 14, 2016, the Federal Drug Enforcement Agency temporarily placed U-47700 in Schedule I for a two-year period, finding that this synthetic opioid has a high potential for abuse, no currently accepted medical use in treatment in the United States and lacks accepted safety for use under medical supervision. By Emergency Order dated December 15, 2016, the Secretary of State temporarily placed U-47700 in Schedule I. This Order is effective for 120 days. The permanent addition of U-47700 to Schedule I is required in the interest of public protection.